Details for New Drug Application (NDA): 203183
✉ Email this page to a colleague
The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
Summary for 203183
Tradename: | CISATRACURIUM BESYLATE |
Applicant: | Fresenius Kabi Usa |
Ingredient: | cisatracurium besylate |
Patents: | 0 |
Pharmacology for NDA: 203183
Physiological Effect | Neuromuscular Nondepolarizing Blockade |
Suppliers and Packaging for NDA: 203183
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CISATRACURIUM BESYLATE | cisatracurium besylate | INJECTABLE;INJECTION | 203183 | ANDA | Fresenius Kabi USA, LLC | 63323-417 | 63323-417-10 | 10 VIAL in 1 CARTON (63323-417-10) / 10 mL in 1 VIAL (63323-417-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2MG BASE/ML | ||||
Approval Date: | Feb 26, 2015 | TE: | AP | RLD: | No |
Complete Access Available with Subscription